Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Featured Event:
5 for ’25
Featured Companies
Latest Video Segment
What This Means
Featuring Xenetic Biosciences
Covered Companies
Covered Companies
Series
What This Means
Featuring: Xenetic Biosciences
April 9, 2025
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.
What This Means
Featuring: Sonnet BioTherapeutics
March 26, 2025
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
What This Means
Featuring: Sonnet BioTherapeutics
March 19, 2025
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of
CEO Connect
Featuring: GRI Bio
March 18, 2025
Marc Hertz, President and CEO of GRI Bio provided an overview of GRI’s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in the following quarter.
Past Events
Closing Bell Series
New to the Street
Live What This Means
New to Virtual Investor
Closing Bell
Live What This Means
Closing Bell Series
New to the Street
Live What This Means
New to Virtual Investor
Closing Bell
Live What This Means
Past Events
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact